home

LATEST ONCOPRESCRIBE UPDATES

• FDA Approves Tucatinib with Trastuzumab for Colorectal Cancer

• FDA Approves BRUKINSA® for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

• TAILORx Long Term Update for Patients with Early Stage Breast Cancer

• Sequential Conditioning and Allogeneic Hematopoietic Cell Transplantation WITHOUT Prior Remission-Induction Chemotherapy in AML

• FDA Approves First Gene Therapy for Bladder Cancer

• FDA Approves Bispecific Antibody LUNSUMIO® for Follicular Lymphoma

• Neoadjuvant Chemotherapy, Endocrine Therapy and Targeted Therapy for Breast Cancer: ASCO Updated Guideline

• Tumor-Infiltrating Lymphocyte Therapy in Advanced Refractory Melanoma

SHOW MORE

FDA
Approvals

Meeting
Updates

Hem/Onc
Updates

Symptom
Management

NEW REGIMENS ADDED

Research Regimens

• TIBSOVO® - for Acute Myeloid Leukemia

• Single Agent LUMAKRAS® - for Non Small Cell Lung Cancer

• KEYTRUDA® - for Malignant Melanoma

• TECENTRIQ® and ABRAXANE® - for Breast Cancer

• KEYTRUDA® plus INLYTA® - for Renal Cancer

Curbside Consultation

Renal Cell Carcinoma Special Issue

Immuno-Oncology

Precision Oncology

• COVID-19 Associated Coagulopathy: Diagnosis and Management

• TTP, HUS and aHUS: Different diseases – Different treatments

• HER2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

• Dual Inhibition Improves Outcomes for Patients with BRAF-Mutated Colorectal Tumors

• FDA Approves ENDARI®, A New Treatment for Sickle Cell Disease

SHOW MORE